


This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

1. (Currently Amended): A compound according to ~~Compounds of the~~ formula I



in which

- D is absent or  
is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A,  $-\text{C}(\text{R}^3)_2]_n\text{-Ar}$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-Het}$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-cycloalkyl}$ ,  $\text{OR}^2$ ,  $\text{N}(\text{R}^2)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^2$ ,  $\text{CON}(\text{R}^2)_2$ ,  $\text{NR}^2\text{COA}$ ,  $\text{NR}^2\text{SO}_2\text{A}$ ,  $\text{COR}^2$ ,  $\text{SO}_2\text{NR}^2$  and/or  $\text{S}(\text{O})_m\text{A}$ , and where, furthermore, one  $\text{CH}_2$  group in the alkylene chain may also be replaced by a  $\text{C}=\text{O}$  group,
- M is a phenyl ring or an aromatic heterocyclic ring, which may contain 1-2 N, O and/or S atoms,
- $\text{R}^1$  and  $\text{R}^{1'}$  are each, independently of one another, H, Hal, A,  $\text{OR}^2$ ,  $\text{N}(\text{R}^2)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^2$ ,  $\text{CON}(\text{R}^2)_2$ ,  $\text{C}(\text{=S})\text{N}(\text{R}^2)_2$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-Ar}$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-Het}$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-cycloalkyl}$ ,  $-\text{C}(\text{R}^3)_2]_n\text{-N}(\text{R}^3)_2$ ,  $\text{CN}$ ,  $-\text{C}(\text{=NH})\text{-NH}_2$  which is unsubstituted or monosubstituted by  $\text{C}(\text{=O})\text{R}^3$ ,  $\text{COOR}^3$ ,  $\text{OR}^3$ ,  $\text{OCOR}^3$ ,  $\text{OCOOR}^3$  or by a conventional amino-protecting group, or



- $R^2$  is H, A,  $-[C(R^3)_2]_n\text{-Ar}$ ,  $-[C(R^3)_2]_n\text{-Het}$ ,  $-[C(R^3)_2]_n\text{-cycloalkyl}$ ,  $-[C(R^3)_2]_n\text{-N}(R^3)_2$  or  $-[C(R^3)_2]_n\text{-OR}^3$ ,
- $R^{2'}$  is H, A,  $-[C(R^3)_2]_n\text{-Ar}'$ ,  $-[C(R^3)_2]_n\text{-Het}'$ ,  $-[C(R^3)_2]_n\text{-cycloalkyl}$ ,  $-[C(R^3)_2]_n\text{-N}(R^3)_2$  or  $-[C(R^3)_2]_n\text{-OR}^3$ ,
- $R^{2''}$  is H, A,  $-[C(R^3)_2]_n\text{-Ar}'$ ,  $-[C(R^3)_2]_n\text{-cycloalkyl}$ ,  $-[C(R^3)_2]_n\text{-N}(R^3)_2$  or  $-[C(R^3)_2]_n\text{-OR}^3$ ,
- $R^3$  is H or A,
- W is a monocyclic or bicyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be monosubstituted or disubstituted by  $R^2$ ,
- X is  $\text{CONR}^2$ ,  $\text{CONR}^2\text{C}(R^3)_2$ ,  $-\text{C}(R^3)_2\text{NR}^2$ ,  $-\text{C}(R^3)_2\text{NR}^2\text{C}(R^3)_2$ ,  $-\text{C}(R^3)_2\text{O}-$ ,  $-\text{C}(R^3)_2\text{OC}(R^3)_2-$  or  $\text{NR}^2\text{CO}$ ,
- Y is alkylene, cycloalkylene, Het-diyl or Ar-diyl,
- T is a monocyclic or bicyclic, saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having from 1 to 4 N, O and/or S atoms which is monosubstituted or disubstituted by  $=\text{S}$ ,  $=\text{NR}^2$ ,  $=\text{N-CN}$ ,  $=\text{N-NO}_2$ ,  $=\text{NOR}^2$ ,  $=\text{NCOR}^2$ ,  $=\text{NCOOR}^2$  or  $=\text{NOCOR}^2$  and may furthermore be monosubstituted, disubstituted or trisubstituted by Hal, A,  $-[C(R^3)_2]_n\text{-Ar}$ ,  $-[C(R^3)_2]_n\text{-Het}$ ,  $-[C(R^3)_2]_n\text{-cycloalkyl}$ ,  $\text{OR}^3$ ,  $\text{N}(R^3)_2$ ,  $\text{NO}_2$ ,  $\text{CN}$ ,  $\text{COOR}^2$ ,  $\text{CON}(R^2)_2$ ,  $\text{NR}^2\text{COA}$ ,  $\text{NR}^2\text{CON}(R^2)_2$ ,  $\text{NR}^2\text{SO}_2\text{A}$ ,  $\text{COR}^2$ ,  $\text{SO}_2\text{NR}^2$  and/or  $\text{S}(\text{O})_m\text{A}$ ,
- A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two  $\text{CH}_2$  groups may be replaced by O or S atoms and/or by  $-\text{CH}=\text{CH}-$  groups, and/or in addition 1-7 H atoms may be replaced by F,
- Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A,  $\text{OR}^3$ ,

$N(R^3)_2$ ,  $NO_2$ ,  $CN$ ,  $COOR^3$ ,  $CON(R^3)_2$ ,  $NR^3COA$ ,  $NR^3CON(R^3)_2$ ,  
 $NR^3SO_2A$ ,  $COR^3$ ,  $SO_2N(R^3)_2$ ,  $S(O)_mA$ ,  $-[C(R^3)_2]_n-COOR^{2'}$  or  
 $-O-[C(R^3)_2]_o-COOR^{2'}$ ,

Ar' is phenyl or benzyl, each of which is unsubstituted or monosubstituted or disubstituted by Hal,

Het is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having from 1 to 4 N, O and/or S atoms, which may be unsubstituted or monosubstituted, disubstituted or trisubstituted by carbonyl oxygen,  $=S$ ,  $=N(R^3)_2$ , Hal, A,  $-[C(R^3)_2]_n-Ar$ ,  $-[C(R^3)_2]_n-Het^1$ ,  $-[C(R^3)_2]_n-cycloalkyl$ ,  $-[C(R^3)_2]_n-OR^{2'}$ ,  $-[C(R^3)_2]_n-N(R^{2'})_2$ ,  $NO_2$ ,  $CN$ ,  $-[C(R^3)_2]_n-COOR^{2'}$ ,  $-[C(R^3)_2]_n-CON(R^{2'})_2$ ,  $-[C(R^3)_2]_n-NR^{2'}COA$ ,  $NR^{2'}CON(R^{2'})_2$ ,  $-[C(R^3)_2]_n-NR^{2'}SO_2A$ ,  $COR^{2'}$ ,  $SO_2NR^{2'}$  and/or  $S(O)_mA$ ,

Het<sup>1</sup> is a monocyclic or bicyclic, saturated, unsaturated or aromatic heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl oxygen,  $=S$ ,  $=N(R^3)_2$ , Hal, A,  $OR^{2''}$ ,  $N(R^{2''})_2$ ,  $NO_2$ ,  $CN$ ,  $COOR^{2''}$ ,  $CON(R^{2''})_2$ ,  $NR^{2''}COA$ ,  $NR^{2''}CON(R^{2''})_2$ ,  $NR^{2''}SO_2A$ ,  $COR^{2''}$ ,  $SO_2NR^{2''}$  and/or  $S(O)_mA$ ,

Hal is F, Cl, Br or I,

n is 0, 1 or 2,

m is 0, 1 or 2,

o is 1, 2 or 3, or

a and pharmaceutically usable derivative, solvate, or stereoisomer derivatives,  
~~solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

2. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

D is absent,

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

3. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which M is a phenyl ring;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~
4. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which
- D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by Hal, A, OR<sup>2</sup> or N(R<sup>2</sup>)<sub>2</sub>, and where, furthermore, one CH<sub>2</sub> group in the alkylene chain may also be replaced by a C=O group;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~
5. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which
- D is a saturated, fully or partially unsaturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O and/or 1 or 2 S atoms, but where at most up to 3 carbon atoms are replaced and where, in addition, the alkylene chain and/or a nitrogen present therein may be monosubstituted, disubstituted or trisubstituted by A or NH<sub>2</sub>;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

6. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

D is absent or is a saturated 3- to 4-membered alkylene chain, in which from 1 to 3 carbon atoms may be replaced by N and/or 1 or 2 carbon atoms may be replaced by 1 or 2 O atoms, but where at most up to 3 carbon atoms are replaced,

and where, in addition, the alkylene chain and/or a nitrogen atom located therein is unsubstituted, or may be monosubstituted or disubstituted by  $\text{NH}_2$ ; ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

7. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

D is absent or is  $-\text{CH}=\text{N}-\text{CH}=\text{CH}-$ ,  $-\text{CH}=\text{CH}-\text{N}=\text{CH}-$ ,  $-\text{NH}-\text{N}=\text{CH}-$ ,  $-\text{CH}=\text{N}-\text{NH}-$ ,  $-\text{O}-\text{N}=\text{CH}-$  or  $-\text{CH}=\text{N}-\text{O}-$ ,

and where, in addition, D is unsubstituted or may be monosubstituted by  $\text{NH}_2$ ; ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

8. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1,

in which

$\text{R}^1$  is H,  $-\text{[C(R}^3\text{)}_2\text{]}_n-\text{N(R}^3\text{)}_2$ ,  $\text{CON(R}^2\text{)}_2$ ,  $\text{C(=S)NH}_2$  or  $\text{N(R}^2\text{)}_2$ , and

$\text{R}^{1'}$  is H;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

9. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

$\text{R}^1$  is H,  $\text{CH}_2\text{NH}_2$ ,  $\text{CONH}_2$ ,  $\text{C(=S)NH}_2$  or  $\text{NH}_2$ , and

$\text{R}^{1'}$  is H;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

10. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

W is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by R<sup>2</sup>;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

11. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

W is cyclohexanediyl, cyclopentanediyl, phenylene, biphenylene, furandiyl, thiophenediyl, pyrrolediyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, pyridinediyl, pyrimidinediyl, pyrrolidinediyl, piperidinediyl or piperazinediyl, each of which is unsubstituted or monosubstituted or disubstituted by R<sup>2</sup>;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

12. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

W is pyrazolediyl, which is unsubstituted or monosubstituted by A;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

13. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

X is CONH, CONHCH<sub>2</sub>, CH<sub>2</sub>NH or CH<sub>2</sub>NHCH<sub>2</sub>;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~

~~including mixtures thereof in all ratios.~~

14. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which  
X is CONH<sub>2</sub>;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,  
including mixtures thereof in all ratios.~~
15. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which  
Y is alkylene or Ar-diyl;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,  
including mixtures thereof in all ratios.~~
16. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which  
Y is phenylene which is unsubstituted or monosubstituted or  
disubstituted by A, Br, Cl or F;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,  
including mixtures thereof in all ratios.~~
17. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which  
T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR<sup>2</sup>, =NOR<sup>2</sup>, =N-CN, =N-NO<sub>2</sub>, =NCOR<sup>2</sup>, =NCOOR<sup>2</sup> or =NOCOR<sup>2</sup>, which is unsubstituted or ~~and may be~~ monosubstituted or disubstituted by A, CON(R<sup>2</sup>)<sub>2</sub> or COOR<sup>2</sup>;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,  
including mixtures thereof in all ratios.~~

18. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which
- T is a monocyclic saturated or unsaturated heterocyclic ring having from 1 to 3 N, O and/or S atoms, which is monosubstituted or disubstituted by =S, =NR<sup>2</sup>, =N-CN or =NOR<sup>2</sup>, which is unsubstituted or ~~and may be~~ monosubstituted or disubstituted by A, CON(R<sup>2</sup>)<sub>2</sub> or COOR<sup>2</sup>, ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~
19. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which
- T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, imidazolidin-1-yl, 1,3,4-thiadiazol-3-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR<sup>2</sup>, =S, =N-CN or =NOR<sup>2</sup> and may furthermore be monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA<sub>5</sub>, ~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~
20. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which
- T is 2-iminopiperidin-1-yl, 2-iminopyrrolidin-1-yl, 2-imino-1*H*-pyridin-1-yl, 3-iminomorpholin-4-yl, 4-imino-1*H*-pyridin-1-yl, 2,6-diiminopiperidin-1-yl, 2-iminopiperazin-1-yl, 2,6-diiminopiperazin-1-yl, 2,5-diiminopyrrolidin-1-yl, 2-imino-1,3-oxazolidin-3-yl, 3-imino-2*H*-pyridazin-2-yl, 2-iminoazepan-1-yl, 2-hydroxy-6-iminopiperazin-1-yl, pyrazol-2-yl, 1,2-dihydropyrazol-2-yl, 2-methoxy-6-iminopiperazin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl, and the corresponding hydroxyimino,



alkoxyimino, thioxo and  $=N-(CH_2)_{1-3}NA'_2$  derivatives, where  $A'$  is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
and where the heterocyclic rings are unsubstituted or may furthermore  
~~be~~ monosubstituted or disubstituted by  $A$ ,  $CONH_2$  or  $COOA_5$   
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

21. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

$T$  is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihydropyrazol-2-yl, and the corresponding hydroxyimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or may furthermore be monosubstituted or disubstituted by  $A$ ,  $CONH_2$  or  $COOA_5$   
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~including mixtures thereof in all ratios.~~

22. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

$D$  is absent or is  $-CH=N-CH=CH-$ ,  $-CH=CH-N=CH-$ ,  $-NH-N=CH-$ ,  $-CH=N-NH-$ ,  $-O-N=CH-$  or  $-CH=N-O-$ ,  
 $M$  is a phenyl ring,  
 $R^1$  is  $H$ ,  $CH_2NH_2$ ,  $CONH_2$ ,  $C(=S)NH_2$  or  $NH_2$ ,  
 $R^{1'}$  is  $H$ ,  
 $W$  is a monocyclic saturated, unsaturated or aromatic carbocyclic or heterocyclic ring having 1 or 2 N, O and/or S atoms, which may be monosubstituted or disubstituted by  $R^2$ ,  
 $R^2$  is  $H$  or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
 $R^{2'}$  is  $H$  or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
 $X$  is  $CONH$ ,  $CONHCH_2$ ,  $CH_2NH$  or  $CH_2NHCH_2$ ,

Y is alkylene or Ar-diyl,  
 Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOH, CONH<sub>2</sub>, NHCOA, NHCONH<sub>2</sub>, NHSO<sub>2</sub>A, COH, SO<sub>2</sub>NH<sub>2</sub>, S(O)<sub>m</sub>A, -(CH<sub>2</sub>)<sub>n</sub>-COOR<sup>2'</sup> or -O-(CH<sub>2</sub>)<sub>o</sub>-COOR<sup>2'</sup>,  
 m and n are each, independently of one another, 0, 1 or 2,  
 o is 1, 2 or 3, and  
 T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and may furthermore be monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA;

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

23. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,  
 M is a phenyl ring,  
 R<sup>1</sup> is H, CH<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, C(=S)NH<sub>2</sub> or NH<sub>2</sub>,  
 R<sup>1'</sup> is H,  
 W is cyclohexanediyl, cyclopentanediy, phenylene, biphenylene, furandiyl, thiophenediy, pyrrolediyl, imidazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, thiazolediyl, isothiazolediyl, pyridinediy, pyrimidinediy or pyrrolidinediy, each of which is unsubstituted or monosubstituted or disubstituted by R<sup>2</sup>,  
 R<sup>2</sup> is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

$R^2$  is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,  
 X is CONH, CONHCH<sub>2</sub>, CH<sub>2</sub>NH or CH<sub>2</sub>NHCH<sub>2</sub>,  
 Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F,  
 A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F, and  
 T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and may furthermore be monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA<sub>5</sub>,

~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

24. (Currently Amended): A compound ~~Compounds of the formula I~~ according to Claim 1, in which

D is absent or is -CH=N-CH=CH-, -CH=CH-N=CH-, -NH-N=CH-, -CH=N-NH-, -O-N=CH- or -CH=N-O-,  
 M is a phenyl ring,  
 $R^1$  is H, CH<sub>2</sub>NH<sub>2</sub>, CONH<sub>2</sub>, C(=S)NH<sub>2</sub> or NH<sub>2</sub>,  
 $R^{1'}$  is H,  
 W is pyrazolediyl or thiazolediyl, each of which is unsubstituted or monosubstituted by A,  
 X is CONH,  
 Y is phenylene which is unsubstituted or monosubstituted or disubstituted by A, Br, Cl or F, and  
 T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl or 3-imino-1,2-dihydropyrazol-2-yl, and the corresponding hydroxyimino,

cyanoimino, alkoxyimino and thioxo derivatives, where the heterocyclic radicals are in each case unsubstituted or may ~~furthermore be~~ monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA,

A is unbranched or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms and/or in addition 1-7 H atoms may be replaced by F;  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.~~

25. (Currently Amended): A compound ~~Compounds~~ according to Claim 1 selected from the group consisting of:

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-imino-5-methyl-3*H*-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(1,5-dimethyl-3-imino-1,2-dihydropyrazol-2-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-aminobenzo[d]isoxazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-amino-1*H*-indazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-thioxopyrrolidin-1-yl)phenyl]-2-(3-amino-1*H*-indazol-5-yl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-thiocarbamoylphenyl)-5-trifluoromethyl-2*H*-pyrazole-3-carboxamide,

N-[4-(2-hydroxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminomethylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[3-methyl-4-(2-methoxyiminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-iminopyrrolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[3-bromo-4-(2-imino-5-methyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-imino-5-methyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-iminoimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-iminoimidazolidin-1-yl)-3-methylphenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-cyanoiminoimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-cyanoimino-3-methylimidazolidin-1-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-imino-5-ethyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-imino-5-aminocarbonyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-imino-5-ethoxycarbonyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-trifluoromethyl-2H-pyrazole-3-carboxamide,

N-[4-(2-imino-5-ethyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-5-(3-aminocarbonylphenyl)-2-methylthiazole-4-carboxamide,


N-[4-(2-imino-5-ethyl-3H-1,3,4-thiadiazol-3-yl)phenyl]-2-(3-aminocarbonylphenyl)-5-methyl-2H-pyrazole-3-carboxamide,

and pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios.

26. (Currently Amended): ~~A process~~ Process for the preparation ~~a compound of~~  
~~compounds of the formula I~~ according to Claim 1, said process comprising:  
~~and pharmaceutically usable derivatives, solvates and stereoisomers thereof,~~  
~~characterised in that~~

- a) for the preparation of a compound ~~of the formula I~~  
in which X is  $\text{CONR}^2$  or  $\text{CONR}^2\text{C}(\text{R}^3)_2$ ,

a compound of the formula II



in which

L is Cl, Br, I or a free or reactively functionally modified OH group,  
~~and  $\text{R}^1$ ,  $\text{R}^{1'}$ , D, M and W are as defined in Claim 1,~~  
with the proviso that any further OH and/or amino group present is protected,

is reacted with a compound of the formula III



in which

$\text{Z}'$  is  $\text{NHR}^2$  or  $\text{NHR}^2\text{C}(\text{R}^3)_2$ ,  
and  $\text{R}^2$ , Y and T are as defined in Claim 1,  
and any protecting group is subsequently removed,

- b) and/or in that a radical T,  $\text{R}^1$  and/or  $\text{R}^{1'}$  ~~in a compound of the formula I~~  
is converted into another radical T,  $\text{R}^1$  and/or  $\text{R}^{1'}$

by, ~~for example,~~

- i) converting a sulfanyl compound into an imino compound,
- ii) removing an amino-protecting group,

and/or

a base or acid of the formula I is converted into one of its salts.

- 27. (Currently Amended): A method of inhibiting coagulation factor Xa in a patient, comprising administering to said patient a compound ~~Compounds of the formula I according to Claim 1 as inhibitors of coagulation factor Xa.~~
- 28. (Currently Amended): A method of inhibiting coagulation factor VIIa in a patient, comprising administering to said patient a compound ~~Compounds of the formula I according to Claim 1 as inhibitors of coagulation factor VIIa.~~
- 29. (Currently Amended): A pharmaceutical composition comprising a ~~Medicament comprising at least one compound of the formula I according to Claim 1 and at least one excipient and/or adjuvant and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.~~
- 30. (Currently Amended): A pharmaceutical composition ~~Medicament comprising at least one compound of the formula I according to Claim 29, further comprising 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.~~
- 31. (Currently Amended): A method for treating ~~Use of compounds according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial~~

infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases in a patient, comprising administering to said patient a compound according to claim 1.

32. (Currently Amended): A kit Set (kit) consisting of separate packs of
- (a) an effective amount of a compound ~~of the formula I~~ according to Claim 1 ~~and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~
  - and
  - (b) an effective amount of a further medicament active ingredient.
33. (Currently Amended): A method according to claim 31, further comprising administering to said patient ~~Use of compounds of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios,~~
- ~~for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases,~~
- ~~in combination with~~ at least one further medicament active ingredient.
34. (New): A compound according to claim 1, wherein
- D is absent,
- M is phenyl,
- W is pyrazolediyl which is unsubstituted or monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA,
- X is CONH,
- Y is Ar-diyl,
- Ar is phenyl which is unsubstituted or monosubstituted, disubstituted or trisubstituted by Hal, A, OH, NH<sub>2</sub>, NO<sub>2</sub>, CN, COOH, CONH<sub>2</sub>, NHCOA,



NHCONH<sub>2</sub>, NHSO<sub>2</sub>A, COH, SO<sub>2</sub>NH<sub>2</sub>, S(O)<sub>m</sub>A, -(CH<sub>2</sub>)<sub>n</sub>-COOR<sup>2'</sup> or -O-(CH<sub>2</sub>)<sub>o</sub>-COOR<sup>2'</sup>, and

T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, pyrazol-2-yl, 1,3,4-thiadiazol-3-yl, imidazolidin-1-yl or 1,2-dihydropyrazol-2-yl, each of which is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and may furthermore be monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA.

35. (New): A compound according to claim 34, wherein T is 2-iminopyrrolidin-1-yl, 2-iminopiperidin-1-yl, 2-imino-1,3,4-thiadiazol-3-yl, 2-iminoimidazolidin-1-yl, 3-imino-1,2-dihydropyrazol-2-yl, 2-hydroxyiminopyrrolidin-1-yl, 2-hydroxyiminopiperidin-1-yl, 2-hydroxyimino-1,3,4-thiadiazol-3-yl, 2-hydroxyiminoimidazolidin-1-yl, 3-hydroxyimino-1,2-dihydropyrazol-2-yl, 2-thioxopyrrolidin-1-yl, 2-thioxopiperidin-1-yl, 2-thioxo-1,3,4-thiadiazol-3-yl, 2-thioxoimidazolidin-1-yl, or 3-thioxo-1,2-dihydropyrazol-2-yl.
36. (New): A compound according to claim 34, wherein T is pyrrolidin-1-yl or 1,3,4-thiadiazol-3-yl which in each case is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and is further optionally monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA.
37. (New): A compound according to claim 36, wherein T is pyrrolidin-1-yl which is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and is further optionally monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA.
38. (New): A compound according to claim 36, wherein T is 1,3,4-thiadiazol-3-yl which is monosubstituted or disubstituted by =NR<sup>2</sup>, =N-CN, =S or =NOR<sup>2</sup> and is further optionally monosubstituted or disubstituted by A, CONH<sub>2</sub> or COOA.
39. (New): A compound according to Claim 34, wherein

$R^1$  is H,  $-[C(R^3)_2]_n-N(R^3)_2$ ,  $CON(R^2)_2$ ,  $C(=S)NH_2$  or  $N(R^2)_2$ , and  
 $R^{1'}$  is H.

40. (New): A compound according to Claim 39, wherein  $R^1$  is H,  $CH_2NH_2$ ,  $CONH_2$ ,  $C(=S)NH_2$  or  $NH_2$ .
41. (New): A compound according to Claim 35, wherein  
 $R^1$  is H,  $-[C(R^3)_2]_n-N(R^3)_2$ ,  $CON(R^2)_2$ ,  $C(=S)NH_2$  or  $N(R^2)_2$ , and  
 $R^{1'}$  is H.
42. (New): A compound according to Claim 41, wherein  $R^1$  is H,  $CH_2NH_2$ ,  $CONH_2$ ,  $C(=S)NH_2$  or  $NH_2$ .
43. (New): A compound according to Claim 37, wherein  
 $R^1$  is H,  $-[C(R^3)_2]_n-N(R^3)_2$ ,  $CON(R^2)_2$ ,  $C(=S)NH_2$  or  $N(R^2)_2$ , and  
 $R^{1'}$  is H.
44. (New): A compound according to Claim 43, wherein  $R^1$  is H,  $CH_2NH_2$ ,  $CONH_2$ ,  $C(=S)NH_2$  or  $NH_2$ .